Imugene Ltd (IMU) - Total Assets
Based on the latest financial reports, Imugene Ltd (IMU) holds total assets worth AU$67.67 Million AUD (≈ $47.88 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore IMU debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Imugene Ltd - Total Assets Trend (1993–2025)
This chart illustrates how Imugene Ltd's total assets have evolved over time, based on quarterly financial data. See IMU total equity for net asset value and shareholders' equity analysis.
Imugene Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Imugene Ltd's total assets of AU$67.67 Million consist of 49.9% current assets and 50.1% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 26.2% |
| Accounts Receivable | AU$10.02 Million | 12.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$1.73 Million | 2.1% |
| Intangible Assets | AU$31.69 Million | 37.9% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1993–2025)
This chart illustrates how Imugene Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Imugene Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Imugene Ltd's current assets represent 49.9% of total assets in 2025, an increase from 2.9% in 1993.
- Cash Position: Cash and equivalents constituted 26.2% of total assets in 2025, up from 0.3% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, a decrease from 70.0% in 1993.
- Asset Diversification: The largest asset category is intangible assets at 37.9% of total assets.
Imugene Ltd Competitors by Total Assets
Key competitors of Imugene Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Imugene Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.78 | 3.08 | 9.86 |
| Quick Ratio | 1.68 | 3.08 | 9.86 |
| Cash Ratio | 0.77 | 1.27 | 8.72 |
| Working Capital | AU$14.15 Million | AU$55.11 Million | AU$33.38 Million |
Imugene Ltd - Advanced Valuation Insights
This section examines the relationship between Imugene Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.37 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | -44.8% |
| Total Assets | AU$83.59 Million |
| Market Capitalization | $25.52 Million USD |
Valuation Analysis
Below Book Valuation: The market values Imugene Ltd's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Imugene Ltd's assets decreased by 44.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Imugene Ltd (1993–2025)
The table below shows the annual total assets of Imugene Ltd from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$83.59 Million ≈ $59.14 Million |
-44.79% |
| 2024-06-30 | AU$151.40 Million ≈ $107.12 Million |
-23.17% |
| 2023-06-30 | AU$197.06 Million ≈ $139.43 Million |
+33.51% |
| 2022-06-30 | AU$147.61 Million ≈ $104.44 Million |
+105.55% |
| 2021-06-30 | AU$71.81 Million ≈ $50.81 Million |
+10.13% |
| 2020-06-30 | AU$65.20 Million ≈ $46.14 Million |
+111.85% |
| 2019-06-30 | AU$30.78 Million ≈ $21.78 Million |
+81.97% |
| 2018-06-30 | AU$16.91 Million ≈ $11.97 Million |
+33.42% |
| 2017-06-30 | AU$12.68 Million ≈ $8.97 Million |
+32.95% |
| 2016-06-30 | AU$9.54 Million ≈ $6.75 Million |
+4.62% |
| 2015-06-30 | AU$9.11 Million ≈ $6.45 Million |
+5.60% |
| 2014-06-30 | AU$8.63 Million ≈ $6.11 Million |
+233.97% |
| 2013-06-30 | AU$2.58 Million ≈ $1.83 Million |
+96.03% |
| 2012-06-30 | AU$1.32 Million ≈ $932.84K |
-71.87% |
| 2011-06-30 | AU$4.69 Million ≈ $3.32 Million |
+14.36% |
| 2010-06-30 | AU$4.10 Million ≈ $2.90 Million |
-28.88% |
| 2009-06-30 | AU$5.76 Million ≈ $4.08 Million |
+11.61% |
| 2008-06-30 | AU$5.16 Million ≈ $3.65 Million |
-1.84% |
| 2007-06-30 | AU$5.26 Million ≈ $3.72 Million |
-27.63% |
| 2006-06-30 | AU$7.27 Million ≈ $5.14 Million |
-19.81% |
| 2005-06-30 | AU$9.06 Million ≈ $6.41 Million |
+50.67% |
| 2004-06-30 | AU$6.02 Million ≈ $4.26 Million |
-26.13% |
| 2003-06-30 | AU$8.14 Million ≈ $5.76 Million |
+864.49% |
| 2002-06-30 | AU$844.39K ≈ $597.46K |
-65.40% |
| 2001-06-30 | AU$2.44 Million ≈ $1.73 Million |
-33.72% |
| 2000-06-30 | AU$3.68 Million ≈ $2.61 Million |
-46.58% |
| 1999-06-30 | AU$6.89 Million ≈ $4.88 Million |
-12.65% |
| 1998-06-30 | AU$7.89 Million ≈ $5.58 Million |
-9.23% |
| 1997-06-30 | AU$8.69 Million ≈ $6.15 Million |
-6.01% |
| 1996-06-30 | AU$9.25 Million ≈ $6.54 Million |
-22.45% |
| 1995-06-30 | AU$11.93 Million ≈ $8.44 Million |
+5.42% |
| 1994-06-30 | AU$11.31 Million ≈ $8.00 Million |
+98.54% |
| 1993-06-30 | AU$5.70 Million ≈ $4.03 Million |
-- |
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more